Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b/4 Study to Verify Clinical Benefit of Aducanumab in Early Alzheimer's Disease
2022-001671-14Phase 3Completed
- Sponsor
- Biogen
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Aducanumab with Placebo (2 arms). Primary endpoint: Change from baseline in CDR-SB score. Started Jul 2022; status: completed.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-001671-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001671-14.